There is no simple answer for this. It is a difficult situation and I would consider a few things in making a decision about what to recommend. These include the course of the patient’s disease, e.g., duration and severity of disease, their current and previous medication history, and the seve...

I think this is tricky question. There is no evidence to support either approach in such a patient. Patient age, previous MI/stroke, current control of CV risk factors, patient adherence, patient preference for the route of administration, family hx of CV disease, number of biologics failed, the cur...